Following a limited submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2015. Refer to TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | etanercept (Enbrel®) | ||
| Formulation | 10 mg powder and solvent for solution for injection, 25 mg powder and solvent for solution for injection, 50 mg solution for injection, 25 mg/ml powder and solvent for solution for injection, 25 mg solution for injection | ||
| Reference number | 1437 | ||
| Indication | Treatment of polyarthritis (rheumatoid factor positive or negative) from 2 to < 4 years of age and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy |
||
| Company | Pfizer Ltd | ||
| BNF chapter | Musculoskeletal & joint diseases | ||
| Assessment type | Limited | ||
| Status | Superseded | ||
| Advice number | 3513 | ||
| NMG meeting date | 23/10/2013 | ||
| AWMSG meeting date | 20/11/2013 | ||
| Ratification by Welsh Government | 06/12/2013 | ||
| Date of issue | 13/12/2013 | ||
| NICE guidance | TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis. The recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication. |
||